View Filing Data

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2016	Oct. 31, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	Emergent BioSolutions Inc.
Entity Central Index Key	0001367644
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		40,498,025
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q3
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2016

Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 298,932	$ 308,304
Accounts receivable, net	69,633	113,906
Inventories	81,160	60,887
Deferred tax assets, current portion, net	0	0
Income tax receivable, net	11,831	6,573
Prepaid expenses and other current assets	18,439	18,458
Current assets of discontinued operations	0	29,282
Total current assets	479,995	537,410
Property, plant and equipment, net	362,544	327,808
In process research and development	0	701
Intangible assets, net	35,419	40,758
Goodwill	41,001	41,001
Deferred tax assets, net	11,286	11,286
Other assets	1,781	2,155
Non-current assets of discontinued operations	0	76,365
Total assets	932,026	1,037,484
Current liabilities:
Accounts payable	46,342	37,970
Accrued expenses and other current liabilities	4,279	6,207
Accrued compensation	32,102	31,998
Notes payable, current portion	20,000	0
Contingent consideration, current portion	2,759	2,109
Provision for chargebacks	0	0
Deferred revenue, current portion	4,824	3,979
Current liabilities of discontinued operations	0	17,348
Total current liabilities	110,306	99,611
Contingent consideration, net of current portion	20,169	23,046
Long-term indebtedness	247,793	246,892
Deferred revenue, net of current portion	4,695	3,426
Other liabilities	1,440	1,258
Non-current liabilities of discontinued operations	0	3,234
Total liabilities	384,403	377,467
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.001 par value; 15,000,000 shares authorized, 0 shares issued and outstanding at both September 30, 2016 and December 31, 2015	0	0
Common stock, $0.001 par value; 200,000,000 shares authorized, 40,910,479 shares issued and 40,487,649 shares outstanding at September 30, 2016; 100,000,000 shares authorized, 39,829,408 shares issued and 39,406,578 shares outstanding at December 31, 2015	41	40
Treasury stock, at cost, 422,830 common shares at both September 30, 2016 and December 31, 2015	(6,420)	(6,420)
Additional paid-in capital	342,888	317,971
Accumulated other comprehensive loss	(3,572)	(2,713)
Retained earnings	214,686	351,139
Total stockholders' equity	547,623	660,017
Total liabilities and stockholders' equity	$ 932,026	$ 1,037,484

Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2016	Dec. 31, 2015
Stockholders' equity:
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	15,000,000	15,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	200,000,000	100,000,000
Common stock, shares issued (in shares)	40,910,479	39,829,408
Common stock, shares outstanding (in shares)	40,487,649	39,406,578
Treasury stock ( in shares)	422,830	422,830

Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands

3 Months Ended

9 Months Ended

Sep. 30, 2016

Sep. 30, 2015

Sep. 30, 2016

Sep. 30, 2015

Revenues:

Product sales

$ 96,698

$ 117,512

$ 208,785

$ 204,563

Contract manufacturing

14,712

11,341

32,455

32,443

Contracts, grants and collaborations

31,504

29,525

95,879

92,541

Total revenues

142,914

158,378

337,119

329,547

Operating expenses:

Cost of product sales and contract manufacturing

39,560

35,240

93,025

73,083

Research and development

27,188

34,179

81,173

93,833

Selling, general and administrative

40,688

25,800

108,328

86,263

Income from operations

35,478

63,159

54,593

76,368

Other income (expense):

Interest income

358

104

764

459

Interest expense

(2,049)

(1,635)

(5,082)

(4,923)

Other income (expense), net

(234)

519

(176)

669

Total other expense, net

(1,925)

(1,012)

(4,494)

(3,795)

Income from continuing operations before provision for income taxes

33,553

62,147

50,099

72,573

Provision for income taxes

13,165

20,059

19,861

23,648

Net Income from continuing operations

20,388

42,088

30,238

48,925

Income (loss) from discontinued operations (net of tax)

952

(5,145)

(15,854)

(19,402)

Net income

$ 21,340

$ 36,943

$ 14,384

$ 29,523

Net income per share - basic:

Income from continuing operations (in dollars per share)

$ 0.50

$ 1.08

$ 0.75

$ 1.28

Income (loss) from discontinued operations (in dollars per share)

0.02

(0.14)

(0.40)

(0.51)

Net income per share - basic (in dollars per share)

0.52

0.94

0.35

0.77

Net income per share - diluted:

Income from continuing operations (in dollars per share)

0.43

^[1]

0.90

^[1]

0.68

1.11

Income (loss) from discontinued operations (in dollars per share)

0.02

(0.11)

(0.32)

(0.42)

Net income per share - diluted (in dollars per share)

$ 0.45

^[1]

$ 0.79

^[1]

$ 0.36

$ 0.69

Weighted-average number of shares - basic (in shares)

40,465,423

38,831,341

40,071,730

38,423,715

Weighted-average number of shares - diluted (in shares)

49,440,313

47,784,550

48,826,597

46,958,179

[1]	See Note 8 "Earnings per share" for details on calculation.

Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Consolidated Statements of Comprehensive Income (Unaudited) [Abstract]
Net income	$ 21,340	$ 36,943	$ 14,384	$ 29,523
Foreign currency translations, net of tax	(492)	(495)	(859)	(1,144)
Comprehensive income	$ 20,848	$ 36,448	$ 13,525	$ 28,379

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Cash flows from operating activities:
Net income (loss)	$ 14,384	$ 29,523
Adjustments to reconcile to net cash provided by (used in) operating activities:
Stock-based compensation expense	14,527	11,802
Depreciation and amortization	28,155	25,859
Income taxes	4,814	15,904
Change in fair value of contingent obligations	(1,253)	(10,898)
Write off of debt issuance costs	0	0
Impairment of in-process research and development	0	9,827
Abandonment of long-lived assets	3,749	0
Excess tax benefits from stock-based compensation	(10,825)	(8,002)
Other	2,467	197
Changes in operating assets and liabilities:
Accounts receivable	45,035	1,749
Inventories	(16,183)	(14,396)
Income taxes	(14,662)	(22,707)
Prepaid expenses and other assets	(3,146)	1,010
Accounts payable	(1,305)	1,902
Accrued expenses and other liabilities	(1,699)	(2,060)
Accrued compensation	(152)	(1,688)
Provision for chargebacks	103	(296)
Deferred revenue	(1,348)	3,663
Net cash provided by operating activities	62,661	41,389
Cash flows from investing activities:
Purchases of property, plant and equipment	(56,243)	(33,631)
Acquisition of Cangene Corporation, net of acquired cash	0	0
Net cash used in investing activities	(56,243)	(33,631)
Cash flows from financing activities:
Proceeds from convertible debenture, net of bank fees	0	0
Proceeds from long-term debt obligations	0	2,000
Issuance of common stock upon exercise of stock options	14,981	15,902
Excess tax benefits from stock-based compensation	10,825	8,002
Distribution of Aptevo	(45,000)	0
Contingent obligation payments	(1,226)	(5,427)
Net cash (used in) provided by financing activities	(20,420)	20,477
Effect of exchange rate changes on cash and cash equivalents	139	(16)
Net (decrease) increase in cash and cash equivalents	(13,863)	28,219
Cash and cash equivalents at beginning of period	312,795	280,499
Cash and cash equivalents at end of period	$ 298,932	$ 308,718

Summary of significant accounting policies	9 Months Ended
Summary of significant accounting policies	Sep. 30, 2016
Summary of significant accounting policies [Abstract]
Summary of significant accounting policies	1. Summary of significant accounting policies Basis of presentation and consolidation On August 6, 2015, Emergent BioSolutions Inc. (the "Company" or "Emergent"), announced its plan to separate into two independent publicly-traded companies. On August 1, 2016, the Company accomplished this plan through the completion of the spin-off of Aptevo Therapeutics Inc. ("Aptevo"), a biotechnology company focused on novel oncology and hematology therapeutics to meaningfully improve patients' lives. Emergent remains as a global specialty life sciences company focused on providing specialty products for civilian and military populations that address intentional and naturally emerging public health threats. In anticipation of the spin-off, the Company realigned certain components of its biosciences business to the new Aptevo segment to be consistent with how the Company's chief operating decision maker ("CODM") allocates resources and makes decisions about the operations of the Company. Effective January 1, 2016, the Company changed its segment presentation to reflect this new structure, and recast all prior periods presented to conform to the new presentation. On August 1, 2016, the Company completed the spin-off of Aptevo. Aptevo is now an independent public company trading under the symbol "APVO" on the NASDAQ Global Select Market ("NASDAQ"). The results of operations and financial position of Aptevo are reflected as discontinued operations for all periods presented through the date of the spin-off. The historical financial statements and footnotes have been revised accordingly. See Note 2. "Discontinued operations" for further details regarding the spin-off. For periods following the spin-off, the Company reports financial results under one business segment. The accompanying unaudited consolidated financial statements include the accounts of Emergent and its subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited consolidated financial statements included herein have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X issued by the Securities and Exchange Commission ("SEC"). Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2015, as filed with the SEC. During the nine months ended September 30, 2016 there have been no significant changes to the Company's summary of significant accounting policies contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2015, as filed with the SEC. In the opinion of the Company's management, any adjustments contained in the accompanying unaudited consolidated financial statements are of a normal recurring nature, except for the adjustments associated with the spin-off of Aptevo, and are necessary to present fairly the financial position of the Company as of September 30, 2016, specifically: the results of operations and comprehensive income for the three and nine months ended September 30, 2016 and 2015; and cash flows for the nine months ended September 30, 2016 and 2015. Interim results are not necessarily indicative of results that may be expected for any other interim period or for an entire year. We analyze our multiple element revenue-generating arrangements to determine whether the elements can be separated and accounted for individually as separate units of accounting. An item can generally be considered a separate unit of accounting if both of the following criteria are met: (1) the delivered item(s) has value to the customer on a stand-alone basis and (2) if the arrangement includes a general right of return and delivery or performance of the undelivered item(s) is considered probable and substantially in our control. Items that cannot be divided into separate units are combined with other units of accounting, as appropriate. Consideration received is allocated among the separate units based on the unit's relative selling price and is recognized in full when the appropriate revenue recognition criteria are met. We deem services to be rendered if no continuing obligation exists on our part. As of September 30, 2016, the Company has determined that its US Government contracts for Anthrasil™ (Anthrax Immune Globulin Intravenous (Human), BAT™ (Botulism Antitoxin Heptavalent (A,B,C,D,E,F,G)-Equine and VIGIV (Vaccinia Immune Globulin Intravenous (Human)) are multiple element arrangements. Recent accounting standards In April 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2014-08, Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity ("ASU No. 2014-08"). ASU No. 2014-08 limits discontinued operations reporting to disposals of components of an entity that represent strategic shifts that have (or will have) a major effect on an entity's operations and financial results. ASU No. 2014-08 also requires expanded disclosures for discontinued operations and disposals of individually significant components of an entity that do not qualify for discontinued operations reporting. ASU No. 2014-08 was effective for disposals and components classified as held-for-sale that occurred within annual periods beginning on or after December 15, 2014, and interim periods within those years. Early adoption was permitted. The new guidance is effective for the Company prospectively for all disposals of components of an entity that occurred after January 1, 2015. The spin-off of Aptevo by the Company on August 1, 2016 meets the definition of a discontinued operation under the new guidance and, as a result, the Company reflected the provisions of the new guidance in the third quarter of 2016. In May 2014, the FASB issued ASU No. 2014-09, Summary and Amendments That Create Revenue from Contracts with Customers (Topic 606) and Other Assets and Deferred Costs—Contracts with Customers (Subtopic 340-40). ASU No. 2014-09 supersedes the revenue recognition requirements in Topic 605, Revenue Recognition, as well as most industry-specific guidance, and significantly enhances comparability of revenue recognition practices across entities and industries by providing a principles-based, comprehensive framework for addressing revenue recognition issues. In order for a provider of promised goods or services to recognize as revenue the consideration that it expects to receive in exchange for the promised goods or services, the provider should apply the following five steps: (1) identify the contract with a customer(s); (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation. ASU No. 2014-09 also specifies the accounting for some costs to obtain or fulfill a contract with a customer and provides enhanced disclosure requirements. The FASB has deferred ASU No. 2014-09 for one year, and with that deferral, the standard will be effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period, which for the Company will be its 2018 first quarter. The Company is permitted to use either the retrospective or the modified retrospective method when adopting ASU No. 2014-09. The Company is still assessing the potential impact that ASU No. 2014-09 will have on its financial statements and disclosures, but believes that there could be changes to the revenue recognition for government contracts. In April 2015, the FASB issued ASU No. 2015-03, Interest - Imputation of Interest (Subtopic 835-30), which simplifies the presentation of debt issuance costs. ASU No. 2015-03 requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. Prior to the issuance of ASU 2015-03, debt issuance costs were required to be presented as an asset on the balance sheet. ASU No. 2015-03 is effective for interim and annual periods beginning after December 15, 2015. The Company has adopted the guidance and has applied the guidance on a retrospective basis. In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718). ASU No. 2016-09 simplifies several aspects of the accounting for share-based payment award transactions, including: (1) the income tax consequences, (2) classification of awards as either equity or liabilities, and (3) classification on the statement of cash flows. ASU No. 2016-09 is effective for the annual reporting period beginning after December 15, 2016, including interim periods within that reporting period, with early adoption permitted. The Company is currently evaluating the impact that the adoption of ASU No. 2016-09 will have on the consolidated financial statements and related disclosures.

Discontinued Operations

9 Months Ended

Sep. 30, 2016

Discontinued Operations [Abstract]

Discontinued Operations

2. Discontinued operations

On August 1, 2016, the Company completed the spin-off of Aptevo through the distribution of 100% of the outstanding shares of common stock of Aptevo to the Company's shareholders (the "Distribution"). The Distribution was made to the Company's shareholders of record as of the close of business on July 22, 2016 (the "Record Date"), who received one share of Aptevo common stock for every two shares of Emergent common stock held as of the Record Date. The Distribution was intended to qualify as a tax-free distribution for federal income tax purposes in the United States. In the aggregate, approximately 20.2 million shares of Aptevo common stock were distributed to the Company's shareholders of record as of the Record Date in the Distribution. After the Distribution, the Company no longer holds shares of Aptevo's common stock. In addition, on August 1, 2016, the Company entered into a non-negotiable, unsecured promissory note with Aptevo to provide an additional $20 million in funding within six to twelve months following the Distribution.

The historical balance sheet and statements of operations of Aptevo have been presented as discontinued operations in the consolidated financial statements and prior periods have been restated. Discontinued operations include results of Aptevo's business except for certain allocated corporate overhead costs and certain costs associated with transition services provided by the Company to Aptevo. These allocated costs remain part of continuing operations. Due to differences between the basis of presentation for discontinued operations and the basis of presentation as a stand-alone company, the financial results of Aptevo included within discontinued operations for the Company may not be indicative of actual financial results of Aptevo.

In conjunction with the spin-off, the Company entered into a Separation and Distribution Agreement with Aptevo to effect the separation of Aptevo from the Company (the "Separation"). The Company also entered into various other agreements to provide a framework for its relationship with Aptevo after the Separation, including a manufacturing services agreement, transition services agreement, a tax matters agreement and an employee matters agreement.

The Separation and Distribution Agreement with Aptevo sets forth, among other things, the assets that were transferred, the liabilities assumed, and the contracts that were assigned to each of Aptevo and the Company as part of the Separation of the Company into two companies, and provided for when and how these transfers, assumptions and assignments were to occur.

Under the terms of the manufacturing services agreement, the Company agreed to provide contract manufacturing services for certain of Aptevo's products commencing on the date of the Distribution. The contract has a term of ten years. For the three and nine months ended September 30, 2016, there has been no revenue under this agreement.

Under the terms of the transition services agreement, the Company agreed to provide on an interim, transitional basis, various services, including, but not limited to, accounts payable administration, information technology services, regulatory and clinical support, general administrative services and other support services commencing on the date of the Distribution and terminating up to two years following the date of the Distribution. During the three and nine months ended September 30, 2016, approximately $0.5 million of transition services revenue associated with the provision of services to Aptevo.

The tax matters agreement governs the respective rights, responsibilities and obligations of Aptevo and the Company with respect to taxes (including taxes arising in the ordinary course of business and taxes, if any, incurred as a result of any failure of the Distribution and certain related transactions to qualify as tax-free for U.S. federal income tax purposes), tax attributes, tax returns, tax proceedings and certain other tax matters.

The employee matters agreement governs certain compensation and employee benefit obligations and allocates liabilities and responsibilities relating to employment matters, employee compensation and benefit plans and programs and other related matters, including the transfer or assignment of employees from the Company to Aptevo.

The following table represents the carrying value of Aptevo's assets and liabilities distributed as part of the Separation on August 1, 2016:

(in thousands)	August 1, 2016

Assets:
Cash and cash equivalents	$	45,000
Accounts receivable, net		4,465
Inventories		11,959
Other current assets		4,870
Current assets of discontinued operations		66,294

Property, plant and equipment, net		6,128
In-process research and development		41,800
Intangible assets, net		15,402
Goodwill		13,902
Non-current assets of discontinued operations		77,232
Total assets of discontinued operations	$	143,526

Liabilities:
Accounts payable	$	6,285
Accrued expenses and other current liabilities		64
Accrued compensation		2,456
Contingent consideration		191
Provisions for chargebacks		2,341
Deferred revenue, current portion		433
Current liabilities of discontinued operations		11,770

Deferred revenue, net of current portion		3,232
Other liabilities		91
Non-current liabilities of discontinued operations		3,323
Total liabilities of discontinued operations	$	15,093

The following table represents Aptevo's assets and liabilities presented as discontinued operations and classified as held-for-disposition as of December 31, 2015:

(in thousands)	December 31, 2015

Assets:
Cash and cash equivalents	$	4,492
Accounts receivable, net		6,861
Inventories		16,049
Prepaid expenses and other current assets		1,880
Current assets of discontinued operations		29,282

Property, plant and equipment, net		4,046
In-process research and development		41,800
Intangible assets, net		16,617
Goodwill		13,902
Non-current assets of discontinued operations		76,365
Total assets of discontinued operations	$	105,647

Liabilities:
Accounts payable	$	8,134
Accrued expenses and other current liabilities		22
Accrued compensation		2,684
Contingent consideration, current portion		306
Provisions for chargebacks		2,238
Deferred revenue, current portion		3,964
Current liabilities of discontinued operations		17,348

Deferred revenue, net of current portion		3,163
Other liabilities		71
Non-current liabilities of discontinued operations		3,234
Total liabilities of discontinued operations	$	20,582

The following table summarizes results from discontinued operations of Aptevo included in the consolidated statements of operations:

	Three Months Ended September 30,						Nine Months Ended September 30,
(in thousands)	2016			2015			2016			2015

Revenues:
Product sales	$	3,019		$	6,441		$	21,183		$	19,704
Collaborations		68			121			187			5,434
Total revenues		3,087			6,562			21,370			25,138

Operating expense:
Cost of product sales		907			3,270			11,556			11,442
Research and development		2,509			7,689			18,024			27,678
Selling, general and administrative		7,499			5,756			23,792			16,239
Loss from operations		(7,828	)		(10,153	)		(32,002	)		(30,221	)

Other income (expense), net:		(116	)		83			(41	)		(464	)

Loss from discontinued operations before benefit from income taxes		(7,944	)		(10,070	)		(32,043	)		(30,685	)
Benefit from income taxes		(8,896	)		(4,925	)		(16,189	)		(11,283	)
Net loss from discontinued operations	$	952		$	(5,145	)	$	(15,854	)	$	(19,402	)

The following table summarizes the cash flows of Aptevo included in the September 30, 2016 and 2015 consolidated statements of cash flows:

	Nine Months Ended September 30,
(in thousands)	2016			2015
Net cash (used in) provided by operating activities	$	(17,813	)	$	1,414
Net cash used in investing activities		(1,925	)		(970	)
Net cash provided by (used in) financing activities		15,247			(679	)

Net increase (decrease) in cash and cash equivalents	$	(4,491	)	$	(235	)

- Definition

The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=65878427&loc=SL51721533-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721665-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721675-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=64862545&loc=SL51724579-110230

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721663-107760

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64862545&loc=d3e2941-110230

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1361-107760

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721673-107760

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721659-107760

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721671-107760

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721677-107760

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1474-107760

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721683-107760

+ Details

Fair value measurements

9 Months Ended

Sep. 30, 2016

Fair value measurements [Abstract]

Fair value measurements

3. Fair value measurements

The following table represents the Company's fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis:

	September 30, 2016
(in thousands)		Level 1		Level 2		Level 3		Total
Assets:
Investment in money market funds (1)		$	10	$	-	$	-	$	10
Total assets		$	10	$	-	$	-	$	10

Liabilities:
Contingent consideration		$	-	$	-	$	22,928	$	22,928
Total liabilities		$	-	$	-	$	22,928	$	22,928

	December 31, 2015
(in thousands)		Level 1		Level 2		Level 3		Total
Assets:
Investment in money market funds (1)		$	3,323	$	-	$	-	$	3,323
Total assets		$	3,323	$	-	$	-	$	3,323

Liabilities:
Contingent consideration		$	-	$	-	$	25,155	$	25,155
Total liabilities		$	-	$	-	$	25,155	$	25,155

(1) Included in cash and cash equivalents in the accompanying consolidated balance sheets.

During the nine months ended September 30, 2016, the Company did not have any transfers between Level 1 and Level 2 assets or liabilities.

For the three months ended September 30, 2016, the contingent consideration obligation associated with the EV-035 series of molecules increased by $0.1 million. For the nine months ended September 30, 2016, the contingent consideration obligation associated with the EV-035 series of molecules decreased by $0.3 million. For the three and nine months ended September 30, 2015, the contingent consideration obligation decreased by $9.9 million and $9.5 million, respectively. These changes are primarily due to the estimated timing and probability of success for certain development and regulatory milestones and the estimated timing and volume of potential future sales of the EV-035 series of molecules and the broad spectrum antiviral platform, which are inputs that have no observable market (Level 3), along with the novation of the Defense Threat Reduction Agency ("DTRA") contract for the EV-035 series of molecules. These decreases and increases in the contingent consideration were classified in the Company's statement of operations as both selling, general and administrative expense and research and development expense. During the nine months ended September 30, 2015, the Company received novation of the DTRA contract and paid the $4.0 million milestone to Evolva in the second quarter of 2015.

For the three and nine months ended September 30, 2016, the contingent purchase consideration obligations associated with RSDL decreased by $2.3 million and $1.0 million, respectively. For the three and nine months ended September 30, 2015, the contingent consideration obligations associated with RSDL decreased by $1.9 million and $1.8 million, respectively. The fair value of the RSDL contingent consideration obligations decreased as a result of management's assessment of the assumed and actual achievement of future net sales, which are inputs that have no observable market (Level 3). These changes are classified in the Company's statement of operations as cost of product sales and contract manufacturing.

The following table is a reconciliation of the beginning and ending balance of the liabilities, consisting only of contingent consideration, measured at fair value using significant unobservable inputs (Level 3) during the nine months ended September 30, 2016.

(in thousands)
Balance at December 31, 2015	$	25,155
Income included in earnings		1,263
Settlements		(964	)
Purchases, sales and issuances		-
Transfers in/(out) of Level 3		-
Balance at September 30, 2016	$	22,928

Separate disclosure is required for assets and liabilities measured at fair value on a recurring basis from those measured at fair value on a non-recurring basis. As of September 30, 2016, the in-process research and development asset for the EV-035 series of molecules was measured at fair value on a non-recurring basis.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Inventories

9 Months Ended

Sep. 30, 2016

Inventories [Abstract]

Inventories

4. Inventories

Inventories consisted of the following:

	September 30,		December 31,
(in thousands)	2016		2015
Raw materials and supplies	$	31,239	$	21,275
Work-in-process		24,459		32,709
Finished goods		25,462		6,903
Total inventories	$	81,160	$	60,887

Property, plant and equipment

9 Months Ended

Sep. 30, 2016

Property, plant and equipment [Abstract]

Property, plant and equipment

5. Property, plant and equipment

Property, plant and equipment consisted of the following:

	September 30,			December 31,
(in thousands)	2016			2015
Land and improvements	$	20,391		$	16,520
Buildings, building improvements and leasehold improvements		141,322			108,908
Furniture and equipment		191,529			129,933
Software		52,744			39,683
Construction-in-progress		64,885			126,531
Property, plant and equipment, gross		470,871			421,575
Less: Accumulated depreciation and amortization		(108,327	)		(93,767	)
Total property, plant and equipment, net	$	362,544		$	327,808

Intangible assets, in-process research and development

9 Months Ended

Sep. 30, 2016

Intangible assets and in-process research and development [Abstract]

Intangible assets, in-process research and development

6. Intangible assets and in-process research and development

Intangible assets consisted of the following:


(in thousands)
Cost basis
Balance at December 31, 2015	$	57,099
Additions		-
Balance at September 30, 2016	$	57,099

Accumulated amortization
Balance at December 31, 2015	$	(16,343	)
Amortization		(5,337	)
Balance at September 30, 2016	$	(21,680	)

Net balance at September 30, 2016	$	35,419

In September 2015, the Company received data for the leading molecule in the EV-035 series of molecules, GC-072, that indicated a potential toxicity issue. The Company considered this information an indicator of impairment of the related EV-035 series of molecules in-process research and development ("IPR&D") asset, and completed an impairment assessment of this asset. Based on this assessment, the Company recorded a non-cash impairment charge of $9.8 million, which is included in the Company's statement of operations as research and development expense. The impairment assessment was performed using the income approach which discounts expected future cash flows to present value. The projected cash flows for the EV-035 series of molecules were based on key assumptions including: estimates of revenues and operating profits considering its stage of development; the time and resources needed to complete the development and approval of the product candidate; the life of the potential commercialized product and associated risks, including the inherent difficulties and uncertainties in developing a product candidate, such as obtaining marketing approval from the FDA and other regulatory agencies; and risks related to the viability of and potential for alternative treatments in any future target markets.

For the three months ended September 30, 2016 and 2015, the Company recorded amortization expense of $1.7 million and $1.8 million, respectively. For the nine months ended September 30, 2016 and 2015, the Company recorded amortization expense of $5.3 million and $5.5 million, respectively, for intangible assets, which has been recorded in operating expenses, specifically selling, general and administrative and cost of product sales and contract manufacturing. As of September 30, 2016, the weighted average amortization period remaining for intangible assets is 78 months.

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

Long-term debt	9 Months Ended
Long-term debt	Sep. 30, 2016
Long-term debt [Abstract]
Long-term debt	7. Long-term debt As of December 31, 2015, the Company reclassified debt issuance costs of $1.2 million and $4.9 million from prepaid expenses and other current assets and other assets, respectively, as a reduction to long-term debt. On January 29, 2014, the Company issued $250.0 million aggregate principal amount of 2.875% Convertible Senior Notes due 2021 (the "Notes"). The Notes mature on January 15, 2021, unless earlier purchased by the Company or converted. The original conversion rate was equal to 30.8821 shares of common stock per $1,000 principal amount of notes (which is equivalent to a conversion price of approximately $32.38 per share of common stock). The conversion rate is subject to adjustment upon the occurrence of certain specified events but will not be adjusted for accrued and unpaid interest. As of August 1, 2016, certain conversion features were triggered due to the completion of the Aptevo spin-off. The conversion rate under the Notes was adjusted in accordance with the terms of the indenture. Effective August 12, 2016, the conversion rate was adjusted to 32.3860 shares of common stock per $1,000 principal amount of notes (which is equivalent to a conversion price of approximately $30.88 per share of common stock).

Equity awards

9 Months Ended

Sep. 30, 2016

Equity awards [Abstract]

Equity awards

8. Equity

As of September 30, 2016, the Company had two stock-based employee compensation plans, the Fourth Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan (the "2006 Plan") and the Emergent BioSolutions Employee Stock Option Plan (the "2004 Plan"). The Company refers to both plans together as the "Emergent Plans." On May 19, 2016, at the Company's annual meeting, the Company's shareholders approved the Fourth Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, and the issuance of 3.8 million shares thereunder. In addition, the Company's shareholders approved an increase in the number of authorized shares of common stock to 200 million shares from 100 million shares.

In connection with the Separation, on August 1, 2016 and in accordance with the employee matters agreement and the Emergent Plans, the Company made certain adjustments to the exercise price and number of equity awards. Continuing Emergent employees with equity awards issued prior to Distribution received an equitable adjustment reflecting a revised exercise price and number of equity awards granted. Continuing Aptevo employees who had been granted Emergent equity awards had their grants canceled and reissued as Aptevo equity awards with an adjusted exercise price.

The following is a summary of stock option award activity:

	2006 Plan					2004 Plan
	Number of Shares			Weighted-Average Exercise Price		Number of Shares			Weighted-Average Exercise Price		Aggregate Intrinsic Value
Outstanding at December 31, 2015		2,964,237		$	22.73		29,699		$	10.28	$	52,119,607
Granted		403,978			33.70		-			-
Exercised		(750,293	)		19.56		(29,699	)		10.28
Forfeited		(62,441	)		27.48		-			-
Canceled		(146,986	)		28.33		-			-
Equitable adjustment		236,313			22.90		-			-
Outstanding at September 30, 2016		2,644,808			22.84		-			-		22,976,804
Exercisable at September 30, 2016		1,558,840		$	19.51		-		$	-	$	18,732,937

The following is a summary of restricted stock unit award activity:

	Number of Shares			Weighted-Average Grant Price		Aggregate Intrinsic Value
Outstanding at December 31, 2015		889,004		$	26.86	$	35,569,048
Granted		488,738			34.36
Vested		(416,289	)		24.68
Forfeited		(46,994	)		29.84
Canceled		(107,514	)		30.90
Equitable adjustment		79,339			28.86
Outstanding at September 30, 2016		886,284		$	28.95	$	24,922,306

On July 14, 2016, the Company's board of directors authorized management to repurchase, from time to time, up to an aggregate of $50 million of the Company's common stock under a board-approved share repurchase program. The timing, amount, and price of any repurchases will be made pursuant to one or more 10b5-1 plans. The term of the board authorization of the repurchase program is until December 31, 2017. The plan will permit shares to be repurchased when the Company might otherwise be precluded from doing so under insider trading laws. The repurchase program may be suspended or discontinued at any time. Any repurchased shares will be available for use in connection with the Company's stock plans and for other corporate purposes. As of September 30, 2016, the Company has neither implemented a repurchase plan nor repurchased any shares under this program.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

Income taxes	9 Months Ended
Income taxes	Sep. 30, 2016
Income taxes [Abstract]
Income taxes	9. Income taxes The estimated effective annual tax rate for continued operations, which excludes discrete adjustments, was 37% and 29%, respectively, for the nine months ended September 30, 2016 and 2015. The increase in the estimated effective annual tax rate on continuing operations was primarily related to tax on the sale, within the Emergent consolidated group, of assets from Canadian subsidiaries to U.S. subsidiaries in preparation of the spin-off of Aptevo and a valuation allowance charge related to Aptevo net deferred tax assets prior to the Distribution, partially offset by a release of valuation allowances associated with Canadian Scientific Research and Experimental Development tax credits.

Earnings per share

9 Months Ended

Sep. 30, 2016

Earnings per share [Abstract]

Earnings per share

10. Earnings per share

The following table presents the calculation of basic and diluted net income (loss) per share:

	Three Months Ended September 30,					Nine Months Ended September 30,
(in thousands, except share and per share data)	2016		2015			2016			2015
Numerator:
Net income from continuing operations	$	20,388	$	42,088		$	30,238		$	48,925
Interest expense, net of tax		934		786			2,234			2,378
Amortization of debt issuance costs, net of tax		183		215			569			671
Net income, adjusted from continuing operations		21,505		43,089			33,041			51,974
Income (loss) from discontinued operations		952		(5,145	)		(15,854	)		(19,402	)
Net income, adjusted	$	22,457	$	37,944		$	17,187		$	32,572

Denominator:
Weighted-average number of shares—basic		40,465,423		38,831,341			40,071,730			38,423,715
Dilutive securities—equity awards		878,390		1,232,684			658,367			813,939
Dilutive securities—convertible debt		8,096,500		7,720,525			8,096,500			7,720,525
Weighted-average number of shares—diluted		49,440,313		47,784,550			48,826,597			46,958,179

Net income per share-basic from continuing operations	$	0.50	$	1.08		$	0.75		$	1.28
Income (loss) per share-basic from discontinued operations		0.02		(0.14	)		(0.40	)		(0.51	)
Net income per share-basic	$	0.52	$	0.94		$	0.35		$	0.77

Net income per share-diluted from continuing operations	$	0.43	$	0.90		$	0.68		$	1.11
Income (loss) per share-diluted from discontinued operations		0.02		(0.11	)		(0.32	)		(0.42	)
Net income per share-diluted	$	0.45	$	0.79		$	0.36		$	0.69

For the three and nine months ended September 30, 2016 and 2015, basic earnings per share is computed by dividing net income by the weighted average number of shares of common stock outstanding during the period.

For the three and nine months ended September 30, 2016 and 2015, diluted earnings per share is computed using the "if-converted" method by dividing the net income adjusted for interest expense and amortization of debt issuance cost, both net of tax, associated with the Company's Notes by the weighted average number of shares of common stock outstanding during the period. The weighted average number of shares is adjusted for the potential dilutive effect of the exercise of stock options and the vesting of restricted stock units along with the assumption of the conversion of the Notes, at the beginning of the period.

For the three months ended September 30, 2016, approximately 0.4 million stock options were excluded from the calculation of diluted earnings per share. For the three and nine months ended September 30, 2015, along with the nine months ended September 30, 2016, substantially all of the outstanding stock options to purchase shares of common stock were included in the calculation of diluted earnings per share.

Restructuring

9 Months Ended

Sep. 30, 2016

Abandonment of equipment

Restructuring

11. Restructuring

In August 2016, the Company adopted a plan to restructure and reprioritize the operations of one of our facilities at the Emergent BioDefense Operations Lansing LLC ("EBOL") site due to the Company's large-scale manufacturing facility at EBOL commencing manufacturing operations. Severance and other related costs and asset-related charges are reflected within the Company's consolidated statement of income as a component of selling, general and administrative expense.

The Company has completed this restructuring. The costs of the restructuring as of September 30, 2016 are detailed below:

	Incurred in		Inception to Date		Total Expected
(in thousands)	2016		Costs Incurred		to be Incurred
Termination benefits	$	2,488	$	2,488	$	5,264
Abandonment of equipment		3,749		3,749		3,749
Other costs		691		691		691
Total	$	6,928	$	6,928	$	9,704

During the nine months ended September 30, 2016, the Company abandoned certain equipment and associated assets at its EBOL facility related to the manufacturing process at Building 12 ("manufacturing process") asset group. The Company recorded a charge for the manufacturing process asset group of $3.7 million. The additional expense is classified in the Company's statements of operations as selling, general and administrative expense. As of September 30, 2016, the Company has determined that there were no indications of impairment for the remaining assets groups at the EBOL site.

The following is a summary of the activity for the liabilities related to the EBOL restructuring:


	Termination
(in thousands)	Benefits
Balance at December 31, 2015	$	-
Expenses incurred		2,488
Amount paid		-
Other adjustments		-
Balance at September 30, 2016	$	2,488

In addition to the above restructuring costs, the Company also recorded a charge of $1.7 million during the nine months ended September 30, 2016 related to retention payments for certain employees at the EBOL site.

Related party transactions	9 Months Ended
Related party transactions	Sep. 30, 2016
Related party transactions [Abstract]
Related party transactions	12. Related party transactions In November 2015, the Company entered into a consulting arrangement with a member of the Company's Board of Directors, amended in July 2016, to provide assistance in connection with the planned spin-off of Aptevo. The total compensation under the agreement was approximately $0.2 million. The consulting agreement terminated on August 1, 2016.

Segment information	9 Months Ended
Segment information	Sep. 30, 2016
Segment information [Abstract]
Segment information	13. Segment information On August 6, 2015, the Company announced its plan to separate into two independent publicly-traded companies. In anticipation of the spin-off, the Company realigned certain components of its biosciences business to the new Aptevo segment to be consistent with how the CODM allocates resources and makes decisions about the operations of the Company. Effective January 1, 2016, the Company changed its segment presentation to reflect this new structure, and recast all prior periods presented to conform to the new presentation. On August 1, 2016, the Company completed the spin-off of Aptevo. The results of operations and financial position of Aptevo are reflected as discontinued operations for all periods presented through the date of the spin-off. For financial reporting purposes, in the periods following the spin-off of Aptevo, the Company reports financial information for one business segment. For the three and nine months ended September 30, 2016 and 2015, substantially all of the Company's revenues are from the United States government.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599

+ Details

Litigation	9 Months Ended
Litigation	Sep. 30, 2016
Litigation [Abstract]
Litigation	14. Litigation On July 19, 2016, Plaintiff William Sponn, or Sponn, filed a putative class action complaint in the United States District Court for the District of Maryland on behalf of purchasers of the Company's common stock between January 11, 2016 and June 21, 2016, inclusive, or the Class Period, seeking to pursue remedies under the Securities Exchange Act of 1934 against the Company and certain of its senior officers and directors, collectively, the Defendants. The complaint alleges, among other things, that the Company made materially false and misleading statements about the government's demand for BioThrax and expectations that the Company's five-year exclusive procurement contract with HHS would be renewed and omitted certain material facts. Sponn is seeking unspecified damages, including legal costs. On October 25, 2016 the Court added City of Cape Coral Municipal Firefighters' Retirement Plan and City of Sunrise Police Officers' Retirement Plan as plaintiffs and appointed them Lead Plaintiffs and Robins Geller Rudman & Dowd LLP as Lead Counsel. The Defendants believe that the allegations in the complaint are without merit and intend to defend themselves vigorously against those claims. As of the date of this filing, the range of potential loss cannot be determined or estimated.

Summary of significant accounting policies (Policies)	9 Months Ended
Summary of significant accounting policies (Policies)	Sep. 30, 2016
Summary of significant accounting policies [Abstract]
Basis of presentation and consolidation	Basis of presentation and consolidation On August 6, 2015, Emergent BioSolutions Inc. (the "Company" or "Emergent"), announced its plan to separate into two independent publicly-traded companies. On August 1, 2016, the Company accomplished this plan through the completion of the spin-off of Aptevo Therapeutics Inc. ("Aptevo"), a biotechnology company focused on novel oncology and hematology therapeutics to meaningfully improve patients' lives. Emergent remains as a global specialty life sciences company focused on providing specialty products for civilian and military populations that address intentional and naturally emerging public health threats. In anticipation of the spin-off, the Company realigned certain components of its biosciences business to the new Aptevo segment to be consistent with how the Company's chief operating decision maker ("CODM") allocates resources and makes decisions about the operations of the Company. Effective January 1, 2016, the Company changed its segment presentation to reflect this new structure, and recast all prior periods presented to conform to the new presentation. On August 1, 2016, the Company completed the spin-off of Aptevo. Aptevo is now an independent public company trading under the symbol "APVO" on the NASDAQ Global Select Market ("NASDAQ"). The results of operations and financial position of Aptevo are reflected as discontinued operations for all periods presented through the date of the spin-off. The historical financial statements and footnotes have been revised accordingly. See Note 2. "Discontinued operations" for further details regarding the spin-off. For periods following the spin-off, the Company reports financial results under one business segment. The accompanying unaudited consolidated financial statements include the accounts of Emergent and its subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited consolidated financial statements included herein have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X issued by the Securities and Exchange Commission ("SEC"). Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2015, as filed with the SEC. During the nine months ended September 30, 2016 there have been no significant changes to the Company's summary of significant accounting policies contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2015, as filed with the SEC. In the opinion of the Company's management, any adjustments contained in the accompanying unaudited consolidated financial statements are of a normal recurring nature, except for the adjustments associated with the spin-off of Aptevo, and are necessary to present fairly the financial position of the Company as of September 30, 2016, specifically: the results of operations and comprehensive income for the three and nine months ended September 30, 2016 and 2015; and cash flows for the nine months ended September 30, 2016 and 2015. Interim results are not necessarily indicative of results that may be expected for any other interim period or for an entire year. We analyze our multiple element revenue-generating arrangements to determine whether the elements can be separated and accounted for individually as separate units of accounting. An item can generally be considered a separate unit of accounting if both of the following criteria are met: (1) the delivered item(s) has value to the customer on a stand-alone basis and (2) if the arrangement includes a general right of return and delivery or performance of the undelivered item(s) is considered probable and substantially in our control. Items that cannot be divided into separate units are combined with other units of accounting, as appropriate. Consideration received is allocated among the separate units based on the unit's relative selling price and is recognized in full when the appropriate revenue recognition criteria are met. We deem services to be rendered if no continuing obligation exists on our part. As of September 30, 2016, the Company has determined that its US Government contracts for Anthrasil™ (Anthrax Immune Globulin Intravenous (Human), BAT™ (Botulism Antitoxin Heptavalent (A,B,C,D,E,F,G)-Equine and VIGIV (Vaccinia Immune Globulin Intravenous (Human)) are multiple element arrangements. Recent accounting standards In April 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2014-08, Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity ("ASU No. 2014-08"). ASU No. 2014-08 limits discontinued operations reporting to disposals of components of an entity that represent strategic shifts that have (or will have) a major effect on an entity's operations and financial results. ASU No. 2014-08 also requires expanded disclosures for discontinued operations and disposals of individually significant components of an entity that do not qualify for discontinued operations reporting. ASU No. 2014-08 was effective for disposals and components classified as held-for-sale that occurred within annual periods beginning on or after December 15, 2014, and interim periods within those years. Early adoption was permitted. The new guidance is effective for the Company prospectively for all disposals of components of an entity that occurred after January 1, 2015. The spin-off of Aptevo by the Company on August 1, 2016 meets the definition of a discontinued operation under the new guidance and, as a result, the Company reflected the provisions of the new guidance in the third quarter of 2016. In May 2014, the FASB issued ASU No. 2014-09, Summary and Amendments That Create Revenue from Contracts with Customers (Topic 606) and Other Assets and Deferred Costs—Contracts with Customers (Subtopic 340-40). ASU No. 2014-09 supersedes the revenue recognition requirements in Topic 605, Revenue Recognition, as well as most industry-specific guidance, and significantly enhances comparability of revenue recognition practices across entities and industries by providing a principles-based, comprehensive framework for addressing revenue recognition issues. In order for a provider of promised goods or services to recognize as revenue the consideration that it expects to receive in exchange for the promised goods or services, the provider should apply the following five steps: (1) identify the contract with a customer(s); (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation. ASU No. 2014-09 also specifies the accounting for some costs to obtain or fulfill a contract with a customer and provides enhanced disclosure requirements. The FASB has deferred ASU No. 2014-09 for one year, and with that deferral, the standard will be effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period, which for the Company will be its 2018 first quarter. The Company is permitted to use either the retrospective or the modified retrospective method when adopting ASU No. 2014-09. The Company is still assessing the potential impact that ASU No. 2014-09 will have on its financial statements and disclosures, but believes that there could be changes to the revenue recognition for government contracts. In April 2015, the FASB issued ASU No. 2015-03, Interest - Imputation of Interest (Subtopic 835-30), which simplifies the presentation of debt issuance costs. ASU No. 2015-03 requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. Prior to the issuance of ASU 2015-03, debt issuance costs were required to be presented as an asset on the balance sheet. ASU No. 2015-03 is effective for interim and annual periods beginning after December 15, 2015. The Company has adopted the guidance and has applied the guidance on a retrospective basis. In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718). ASU No. 2016-09 simplifies several aspects of the accounting for share-based payment award transactions, including: (1) the income tax consequences, (2) classification of awards as either equity or liabilities, and (3) classification on the statement of cash flows. ASU No. 2016-09 is effective for the annual reporting period beginning after December 15, 2016, including interim periods within that reporting period, with early adoption permitted. The Company is currently evaluating the impact that the adoption of ASU No. 2016-09 will have on the consolidated financial statements and related disclosures.

Discontinued Operations (Tables)

9 Months Ended

Sep. 30, 2016

Discontinued Operations [Abstract]

Summary of assets and liabilities presented as discontinued operations

The following table represents the carrying value of Aptevo's assets and liabilities distributed as part of the Separation on August 1, 2016:

(in thousands)	August 1, 2016

Assets:
Cash and cash equivalents	$	45,000
Accounts receivable, net		4,465
Inventories		11,959
Other current assets		4,870
Current assets of discontinued operations		66,294

Property, plant and equipment, net		6,128
In-process research and development		41,800
Intangible assets, net		15,402
Goodwill		13,902
Non-current assets of discontinued operations		77,232
Total assets of discontinued operations	$	143,526

Liabilities:
Accounts payable	$	6,285
Accrued expenses and other current liabilities		64
Accrued compensation		2,456
Contingent consideration		191
Provisions for chargebacks		2,341
Deferred revenue, current portion		433
Current liabilities of discontinued operations		11,770

Deferred revenue, net of current portion		3,232
Other liabilities		91
Non-current liabilities of discontinued operations		3,323
Total liabilities of discontinued operations	$	15,093

The following table represents Aptevo's assets and liabilities presented as discontinued operations and classified as held-for-disposition as of December 31, 2015:

(in thousands)	December 31, 2015

Assets:
Cash and cash equivalents	$	4,492
Accounts receivable, net		6,861
Inventories		16,049
Prepaid expenses and other current assets		1,880
Current assets of discontinued operations		29,282

Property, plant and equipment, net		4,046
In-process research and development		41,800
Intangible assets, net		16,617
Goodwill		13,902
Non-current assets of discontinued operations		76,365
Total assets of discontinued operations	$	105,647

Liabilities:
Accounts payable	$	8,134
Accrued expenses and other current liabilities		22
Accrued compensation		2,684
Contingent consideration, current portion		306
Provisions for chargebacks		2,238
Deferred revenue, current portion		3,964
Current liabilities of discontinued operations		17,348

Deferred revenue, net of current portion		3,163
Other liabilities		71
Non-current liabilities of discontinued operations		3,234
Total liabilities of discontinued operations	$	20,582

Summarized results of discontinued operations included in consolidated statements of income

The following table summarizes results from discontinued operations of Aptevo included in the consolidated statements of operations:

	Three Months Ended September 30,						Nine Months Ended September 30,
(in thousands)	2016			2015			2016			2015

Revenues:
Product sales	$	3,019		$	6,441		$	21,183		$	19,704
Collaborations		68			121			187			5,434
Total revenues		3,087			6,562			21,370			25,138

Operating expense:
Cost of product sales		907			3,270			11,556			11,442
Research and development		2,509			7,689			18,024			27,678
Selling, general and administrative		7,499			5,756			23,792			16,239
Loss from operations		(7,828	)		(10,153	)		(32,002	)		(30,221	)

Other income (expense), net:		(116	)		83			(41	)		(464	)

Loss from discontinued operations before benefit from income taxes		(7,944	)		(10,070	)		(32,043	)		(30,685	)
Benefit from income taxes		(8,896	)		(4,925	)		(16,189	)		(11,283	)
Net loss from discontinued operations	$	952		$	(5,145	)	$	(15,854	)	$	(19,402	)

Summary of disposal groups including discontinued operations cash flow

The following table summarizes the cash flows of Aptevo included in the September 30, 2016 and 2015 consolidated statements of cash flows:

	Nine Months Ended September 30,
(in thousands)	2016			2015
Net cash (used in) provided by operating activities	$	(17,813	)	$	1,414
Net cash used in investing activities		(1,925	)		(970	)
Net cash provided by (used in) financing activities		15,247			(679	)

Net increase (decrease) in cash and cash equivalents	$	(4,491	)	$	(235	)

Fair value measurements (Tables)

9 Months Ended

Sep. 30, 2016

Fair value measurements [Abstract]

Fair Value Hierarchy for Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis

The following table represents the Company's fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis:

	September 30, 2016
(in thousands)		Level 1		Level 2		Level 3		Total
Assets:
Investment in money market funds (1)		$	10	$	-	$	-	$	10
Total assets		$	10	$	-	$	-	$	10

Liabilities:
Contingent consideration		$	-	$	-	$	22,928	$	22,928
Total liabilities		$	-	$	-	$	22,928	$	22,928

	December 31, 2015
(in thousands)		Level 1		Level 2		Level 3		Total
Assets:
Investment in money market funds (1)		$	3,323	$	-	$	-	$	3,323
Total assets		$	3,323	$	-	$	-	$	3,323

Liabilities:
Contingent consideration		$	-	$	-	$	25,155	$	25,155
Total liabilities		$	-	$	-	$	25,155	$	25,155

(1) Included in cash and cash equivalents in the accompanying consolidated balance sheets.

Reconciliation of Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Level 3)

(in thousands)
Balance at December 31, 2015	$	25,155
Income included in earnings		1,263
Settlements		(964	)
Purchases, sales and issuances		-
Transfers in/(out) of Level 3		-
Balance at September 30, 2016	$	22,928

Inventories (Tables)

9 Months Ended

Sep. 30, 2016

Inventories [Abstract]

Inventories

Inventories consisted of the following:

	September 30,		December 31,
(in thousands)	2016		2015
Raw materials and supplies	$	31,239	$	21,275
Work-in-process		24,459		32,709
Finished goods		25,462		6,903
Total inventories	$	81,160	$	60,887

Property, plant and equipment (Tables)

9 Months Ended

Sep. 30, 2016

Property, plant and equipment [Abstract]

Property, plant and equipment

Property, plant and equipment consisted of the following:

	September 30,			December 31,
(in thousands)	2016			2015
Land and improvements	$	20,391		$	16,520
Buildings, building improvements and leasehold improvements		141,322			108,908
Furniture and equipment		191,529			129,933
Software		52,744			39,683
Construction-in-progress		64,885			126,531
Property, plant and equipment, gross		470,871			421,575
Less: Accumulated depreciation and amortization		(108,327	)		(93,767	)
Total property, plant and equipment, net	$	362,544		$	327,808

Intangible assets, in-process research and development (Tables)

9 Months Ended

Sep. 30, 2016

Intangible assets and in-process research and development [Abstract]

Intangible Assets

Intangible assets consisted of the following:


(in thousands)
Cost basis
Balance at December 31, 2015	$	57,099
Additions		-
Balance at September 30, 2016	$	57,099

Accumulated amortization
Balance at December 31, 2015	$	(16,343	)
Amortization		(5,337	)
Balance at September 30, 2016	$	(21,680	)

Net balance at September 30, 2016	$	35,419

Equity awards (Tables)

9 Months Ended

Sep. 30, 2016

Equity awards [Abstract]

Option Award Activity

The following is a summary of stock option award activity:

	2006 Plan					2004 Plan
	Number of Shares			Weighted-Average Exercise Price		Number of Shares			Weighted-Average Exercise Price		Aggregate Intrinsic Value
Outstanding at December 31, 2015		2,964,237		$	22.73		29,699		$	10.28	$	52,119,607
Granted		403,978			33.70		-			-
Exercised		(750,293	)		19.56		(29,699	)		10.28
Forfeited		(62,441	)		27.48		-			-
Canceled		(146,986	)		28.33		-			-
Equitable adjustment		236,313			22.90		-			-
Outstanding at September 30, 2016		2,644,808			22.84		-			-		22,976,804
Exercisable at September 30, 2016		1,558,840		$	19.51		-		$	-	$	18,732,937

Restricted Stock Units Activity

The following is a summary of restricted stock unit award activity:

	Number of Shares			Weighted-Average Grant Price		Aggregate Intrinsic Value
Outstanding at December 31, 2015		889,004		$	26.86	$	35,569,048
Granted		488,738			34.36
Vested		(416,289	)		24.68
Forfeited		(46,994	)		29.84
Canceled		(107,514	)		30.90
Equitable adjustment		79,339			28.86
Outstanding at September 30, 2016		886,284		$	28.95	$	24,922,306

Earnings per share (Tables)

9 Months Ended

Sep. 30, 2016

Earnings per share [Abstract]

Summary of Basic and Diluted Net Income (Loss) per Share

The following table presents the calculation of basic and diluted net income (loss) per share:

	Three Months Ended September 30,					Nine Months Ended September 30,
(in thousands, except share and per share data)	2016		2015			2016			2015
Numerator:
Net income from continuing operations	$	20,388	$	42,088		$	30,238		$	48,925
Interest expense, net of tax		934		786			2,234			2,378
Amortization of debt issuance costs, net of tax		183		215			569			671
Net income, adjusted from continuing operations		21,505		43,089			33,041			51,974
Income (loss) from discontinued operations		952		(5,145	)		(15,854	)		(19,402	)
Net income, adjusted	$	22,457	$	37,944		$	17,187		$	32,572

Denominator:
Weighted-average number of shares—basic		40,465,423		38,831,341			40,071,730			38,423,715
Dilutive securities—equity awards		878,390		1,232,684			658,367			813,939
Dilutive securities—convertible debt		8,096,500		7,720,525			8,096,500			7,720,525
Weighted-average number of shares—diluted		49,440,313		47,784,550			48,826,597			46,958,179

Net income per share-basic from continuing operations	$	0.50	$	1.08		$	0.75		$	1.28
Income (loss) per share-basic from discontinued operations		0.02		(0.14	)		(0.40	)		(0.51	)
Net income per share-basic	$	0.52	$	0.94		$	0.35		$	0.77

Net income per share-diluted from continuing operations	$	0.43	$	0.90		$	0.68		$	1.11
Income (loss) per share-diluted from discontinued operations		0.02		(0.11	)		(0.32	)		(0.42	)
Net income per share-diluted	$	0.45	$	0.79		$	0.36		$	0.69

Restructuring (Tables)

9 Months Ended

Sep. 30, 2016

Abandonment of equipment

Costs of the restructuring

The Company has completed this restructuring. The costs of the restructuring as of September 30, 2016 are detailed below:

	Incurred in		Inception to Date		Total Expected
(in thousands)	2016		Costs Incurred		to be Incurred
Termination benefits	$	2,488	$	2,488	$	5,264
Abandonment of equipment		3,749		3,749		3,749
Other costs		691		691		691
Total	$	6,928	$	6,928	$	9,704

Summary of the activity for liabilities related to EPDU restructuring

The following is a summary of the activity for the liabilities related to the EBOL restructuring:


	Termination
(in thousands)	Benefits
Balance at December 31, 2015	$	-
Expenses incurred		2,488
Amount paid		-
Other adjustments		-
Balance at September 30, 2016	$	2,488

Summary of significant accounting policies (Details)	9 Months Ended
Summary of significant accounting policies (Details)	Sep. 30, 2016 Company
Summary of significant accounting policies [Abstract]
Number of independent public companies	2

Discontinued Operations (Details) - USD ($)	3 Months Ended		9 Months Ended
Discontinued Operations (Details) - USD ($)	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Aug. 01, 2016	Dec. 31, 2015
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Percentage of outstanding shares distributed					100.00%
Record date for distribution			Jul. 22, 2016
Number of common stock distributed (in shares)					20,230,000
Assets [Abstract]
Current assets of discontinued operations	$ 0		$ 0			$ 29,282,000
Non-current assets of discontinued operations	0		0			76,365,000
Liabilities [Abstract]
Current liabilities of discontinued operations	0		0			17,348,000
Non-current liabilities of discontinued operations	0		0			3,234,000
Aptevo [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Unsecured debt					$ 20,000,000
TSA revenue from Aptevo	548,700		548,700
Revenues [Abstract]
Product sales	3,019,000	$ 6,441,000	21,183,000	$ 19,704,000
Contracts, grants and collaborations	68,000	121,000	187,000	5,434,000
Total revenues	3,087,000	6,562,000	21,370,000	25,138,000
Operating expense [Abstract]
Cost of product sales	907,000	3,270,000	11,556,000	11,442,000
Research and development	2,509,000	7,689,000	18,024,000	27,678,000
Selling, general and administrative	7,499,000	5,756,000	23,792,000	16,239,000
Income (loss) from operations	(7,828,000)	(10,153,000)	(32,002,000)	(30,221,000)
Other income (expense), net [Abstract]
Other income (expense), net	(116,000)	83,000	(41,000)	(464,000)
Income (loss) from discontinued operations before provision for (benefit from) income taxes	(7,944,000)	(10,070,000)	(32,043,000)	(30,685,000)
Provision for (benefit from) income taxes	(8,896,000)	(4,925,000)	(16,189,000)	(11,283,000)
Net Income (loss) from discontinued operations	$ 952,000	$ (5,145,000)	(15,854,000)	(19,402,000)
Net Cash Provided by (Used in) Discontinued Operations [Abstract]
Net cash used in operating activities			(17,813,000)	1,414,000
Net cash provided by investing activities			(1,925,000)	(970,000)
Net cash provided by financing activities			15,247,000	(679,000)
Net increase in cash and cash equivalents			$ (4,491,000)	$ (235,000)
Aptevo [Member] \| Disposed of by Sale [Member]
Assets [Abstract]
Cash and cash equivalents					45,000,000
Accounts receivable, net					4,465,000
Inventories					11,959,000
Other current assets					4,870,000
Current assets of discontinued operations					66,294,000
Property, plant and equipment, net					6,128,000
In-process research and development					41,800,000
Intangible assets, net					15,402,000
Goodwill					13,902,000
Non-current assets of discontinued operations					77,232,000
Total assets of discontinued operations					143,526,000
Liabilities [Abstract]
Accounts payable					6,285,000
Accrued expenses and other current liabilities					64,000
Accrued compensation					2,456,000
Contingent consideration, current portion					191,000
Provision for chargebacks					2,341,000
Deferred revenue, current portion					433,000
Current liabilities of discontinued operations					11,770,000
Deferred revenue, net of current portion					3,232,000
Other liabilities					91,000
Non-current liabilities of discontinued operations					3,323,000
Total liabilities of discontinued operations					$ 15,093,000
Aptevo [Member] \| Held-for-sale [Member]
Assets [Abstract]
Cash and cash equivalents						4,492,000
Accounts receivable, net						6,861,000
Inventories						16,049,000
Deferred tax assets, current portion, net						0
Income tax receivable net						0
Prepaid expenses and other current assets						1,880,000
Current assets of discontinued operations						29,282,000
Property, plant and equipment, net						4,046,000
In-process research and development						41,800,000
Intangible assets, net						16,617,000
Goodwill						13,902,000
Non-current assets of discontinued operations						76,365,000
Total assets of discontinued operations						105,647,000
Liabilities [Abstract]
Accounts payable						8,134,000
Accrued expenses and other current liabilities						22,000
Accrued compensation						2,684,000
Contingent consideration, current portion						306,000
Provision for chargebacks						2,238,000
Deferred revenue, current portion						3,964,000
Current liabilities of discontinued operations						17,348,000
Deferred revenue, net of current portion						3,163,000
Other liabilities						71,000
Non-current liabilities of discontinued operations						3,234,000
Total liabilities of discontinued operations						$ 20,582,000

Fair value measurements (Details) - USD ($)
$ in Thousands

3 Months Ended

9 Months Ended

Sep. 30, 2016

Sep. 30, 2015

Sep. 30, 2016

Sep. 30, 2015

Dec. 31, 2015

Dec. 17, 2014

Unobservable Input Reconciliation [Roll Forward]

Balance, beginning of period

$ 25,155

Expense included in earnings

1,263

Settlements

(964)

Purchases, sales and issuances

Transfers in/(out) of Level 3

Balance, end of period

$ 22,928

22,928

Evolva Holding SA 035 & Broad Spectrum Antiviral Platform [Member]

Unobservable Input Reconciliation [Roll Forward]

Change in fair value of contingent obligations

100

$ (9,900)

(300)

$ (9,500)

Contingent value rights based on the novation of the contract

$ 4,000

RSDL [Member]

Unobservable Input Reconciliation [Roll Forward]

Change in fair value of contingent obligations

(2,300)

$ (1,900)

(1,000)

$ (1,800)

Fair Value, Measurements, Recurring [Member]

Assets [Abstract]

Investment in money market funds (1)

^[1]

$ 3,323

Total assets

3,323

Liabilities [Abstract]

Contingent consideration

22,928

25,155

Total liabilities

22,928

25,155

Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]

Assets [Abstract]

Investment in money market funds (1)

^[1]

3,323

Total assets

3,323

Liabilities [Abstract]

Contingent consideration

Total liabilities

Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]

Assets [Abstract]

Investment in money market funds (1)

^[1]

Total assets

Liabilities [Abstract]

Contingent consideration

Total liabilities

Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]

Assets [Abstract]

Investment in money market funds (1)

^[1]

Total assets

Liabilities [Abstract]

Contingent consideration

22,928

25,155

Total liabilities

$ 22,928

$ 25,155

[1]	Included in cash and cash equivalents in accompanying consolidated balance sheets

Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Inventories [Abstract]
Raw materials and supplies	$ 31,239	$ 21,275
Work-in-process	24,459	32,709
Finished goods	25,462	6,903
Total inventories	$ 81,160	$ 60,887

Property, plant and equipment (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Property, plant and equipment	$ 470,871		$ 421,575
Less: Accumulated depreciation and amortization	(108,327)		(93,767)
Total Property, plant and equipment, net	362,544		327,808
Depreciation and amortization	28,155	$ 25,859
Land and Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment	20,391		16,520
Buildings, Building Improvements and Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment	141,322		108,908
Furniture and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment	191,529		129,933
Software [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment	52,744		39,683
Construction-in-progress [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment	$ 64,885		$ 126,531

Intangible assets, in-process research and development (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Accumulated Amortization [Abstract]
Amortization	$ 1,651,000	$ 1,844,000	$ 5,337,000	$ 5,532,000
Intangible assets, weighted average useful life			78 months
Biodefense [Member]
Cost Basis [Abstract]
Intangible Assets, Beginning Balance			$ 57,099,000
Additions			0
Intangible Assets, Ending Balance	57,099,000		57,099,000
Accumulated Amortization [Abstract]
Accumulated Amortization, Beginning Balance			(16,343,000)
Accumulated Amortization, Ending Balance	(21,680,000)		(21,680,000)
Net book value of intangible assets	$ 35,419,000		$ 35,419,000

Long-term debt (Details) $ / shares in Units, $ in Millions		1 Months Ended
Long-term debt (Details) $ / shares in Units, $ in Millions	Aug. 12, 2016 shares $ / shares	Jan. 29, 2014 USD ($) shares $ / shares	Dec. 31, 2015 USD ($)
Amount of debt issuance costs in prepaid expenses and other current assets, netted against long term debt [Member]
Long-Term Debt [Line Items]
Debt issuance costs			$ 1.2
Amount of debt issuance costs in other assets, netted against long term debt [Member]
Long-Term Debt [Line Items]
Debt issuance costs			$ 4.9
Convertible Senior Notes Due 2021 [Member]
Long-Term Debt [Line Items]
Face amount of debt instrument		$ 250.0
Interest rate, stated percentage		2.875%
Maturity date		Jan. 15, 2021
Conversion rate of notes per $1,000 principal amount (in shares) \| shares	32.3860	30.8821
Conversion price per share (in dollars per share) \| $ / shares	$ 30.88	$ 32.38

Equity awards (Details)	9 Months Ended
Equity awards (Details)	Sep. 30, 2016 USD ($) Plan $ / shares shares	Jul. 14, 2016 USD ($)
Equity awards [Abstract]
Number of stock-based employee compensation plans \| Plan	2
Aggregate intrinsic value [Abstract]
Stock Repurchase Program, Authorized Amount \| $		$ 50,000,000
Stock Options Member [Member]
Aggregate Intrinsic Value [Abstract]
Outstanding, beginning of period \| $	$ 52,119,607
Outstanding, end of period \| $	22,976,804
Exercisable, end of period \| $	$ 18,732,937
2006 Plan [Member] \| Restricted Stock Units (RSUs) [Member]
Restricted stock unit award activity [Roll Forward]
Outstanding, beginning of period (in shares)	889,004
Granted (in shares)	488,738
Vested (in shares)	(416,289)
Forfeited (in shares)	(46,994)
Cancelled (in shares)	(107,514)
Equitable adjustment (in shares)	79,339
Outstanding, end of period (in shares)	886,284
Weighted-Average Grant Price [Roll Forward]
Outstanding, beginning of period (in dollars per share) \| $ / shares	$ 26.86
Granted (in dollars per share) \| $ / shares	34.36
Vested (in dollars per share) \| $ / shares	24.68
Forfeited (in dollars per share) \| $ / shares	29.84
Cancelled (in dollars per share) \| $ / shares	30.90
Equitable adjustment (in dollars per share) \| $ / shares	28.86
Outstanding, end of period (in dollars per share) \| $ / shares	$ 28.95
Aggregate intrinsic value [Abstract]
Outstanding, beginning of period \| $	$ 35,569,048
Outstanding, end of period \| $	$ 24,922,306
2006 Plan [Member] \| Stock Options Member [Member]
Options outstanding [Roll Forward]
Outstanding, beginning of period (in shares)	2,964,237
Granted (in shares)	403,978
Exercised (in shares)	(750,293)
Forfeited (in shares)	(62,441)
Cancelled (in shares)	(146,986)
Equitable adjustment (in shares)	236,313
Outstanding, end of period (in shares)	2,644,808
Exercisable, end of period (in shares)	1,558,840
Weighted-Average Exercise Price [Roll Forward]
Outstanding, beginning of period (in dollars per share) \| $ / shares	$ 22.73
Granted (in dollars per share) \| $ / shares	33.70
Exercised (in dollars per share) \| $ / shares	19.56
Forfeited (in dollars per share) \| $ / shares	27.48
Cancelled (in dollars per share) \| $ / shares	28.33
Equitable adjustment (in dollars per share) \| $ / shares	22.90
Outstanding, end of period (in dollars per share) \| $ / shares	22.84
Exercisable, end of period (in dollars per share) \| $ / shares	$ 19.51
Aggregate intrinsic value [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized	3,800,000
2004 Plan [Member] \| Stock Options Member [Member]
Options outstanding [Roll Forward]
Outstanding, beginning of period (in shares)	29,699
Granted (in shares)	0
Exercised (in shares)	(29,699)
Forfeited (in shares)	0
Cancelled (in shares)	0
Equitable adjustment (in shares)	0
Outstanding, end of period (in shares)	0
Exercisable, end of period (in shares)	0
Weighted-Average Exercise Price [Roll Forward]
Outstanding, beginning of period (in dollars per share) \| $ / shares	$ 10.28
Granted (in dollars per share) \| $ / shares	0
Exercised (in dollars per share) \| $ / shares	10.28
Forfeited (in dollars per share) \| $ / shares	0
Cancelled (in dollars per share) \| $ / shares	0
Equitable adjustment (in dollars per share) \| $ / shares	0
Outstanding, end of period (in dollars per share) \| $ / shares	0
Exercisable, end of period (in dollars per share) \| $ / shares	$ 0

Income taxes (Details)	9 Months Ended
Income taxes (Details)	Sep. 30, 2016	Sep. 30, 2015
Income taxes [Abstract]
Effective annual tax rate	37.00%	29.00%

Earnings per share (Details) - USD ($)
$ / shares in Units, $ in Thousands

3 Months Ended

9 Months Ended

Sep. 30, 2016

Sep. 30, 2015

Sep. 30, 2016

Sep. 30, 2015

Numerator [Abstract]

Net Income from continuing operations

$ 20,388

$ 42,088

$ 30,238

$ 48,925

Interest expense, net of tax

934

786

2,234

2,378

Amortization of debt issuance costs, net of tax

183

215

569

671

Net income, adjusted from continuing operations

21,505

43,089

33,041

51,974

Income (loss) from discontinued operations

952

(5,145)

(15,854)

(19,402)

Net income (loss), adjusted

$ 22,457

$ 37,944

$ 17,187

$ 32,572

Denominator [Abstract]

Weighted-average number of shares-basic (in shares)

40,465,423

38,831,341

40,071,730

38,423,715

Dilutive securities-equity awards (in shares)

878,390

1,232,684

658,367

813,939

Dilutive securities-convertible debt

8,096,500

7,720,525

8,096,500

7,720,525

Weighted-average number of shares-diluted (in shares)

49,440,313

47,784,550

48,826,597

46,958,179

Net income per share - basic from continuing operations (in dollars per share)

$ 0.50

$ 1.08

$ 0.75

$ 1.28

Income (loss) per share - basic from discontinued operations (in dollars per share)

0.02

(0.14)

(0.40)

(0.51)

Net income per share - basic (in dollars per share)

0.52

0.94

0.35

0.77

Net income per share - diluted from continuing operations (in dollars per share)

0.43

^[1]

0.90

^[1]

0.68

1.11

Income (loss) per share - diluted from discontinued operations (in dollars per share)

0.02

(0.11)

(0.32)

(0.42)

Net income per share - diluted (in dollars per share)

$ 0.45

^[1]

$ 0.79

^[1]

$ 0.36

$ 0.69

Stock Options [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Antidilutive shares excluded from calculation (in shares)

400,000

Convertible debt [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Antidilutive shares excluded from calculation (in shares)

[1]	See Note 8 "Earnings per share" for details on calculation.

Restructuring (Details) - USD ($) $ in Thousands	9 Months Ended
Restructuring (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Sep. 30, 2015
Summary of activity for liabilities [Roll Forward]
Impairment of idled equipment	$ 3,749	$ 0
Selling, General and Administrative Expenses [Member]
Summary of activity for liabilities [Roll Forward]
Impairment of idled equipment	3,700
EBOL Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Incurred in 2016	6,928
Inception to Date Costs Incurred	6,928
Total Expected to be Incurred	9,704
Termination benefits [Member] \| EBOL Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Incurred in 2016	2,488
Inception to Date Costs Incurred	2,488
Total Expected to be Incurred	5,264
Summary of activity for liabilities [Roll Forward]
Balance, beginning of period	0
Expenses incurred	2,488
Amount paid	0
Other adjustments	0
Balance, end of period	2,488
Other costs [Member] \| EBOL Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Incurred in 2016	691
Inception to Date Costs Incurred	691
Total Expected to be Incurred	691
Abandonment of Equipment [Member] \| EBOL Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Incurred in 2016	3,749
Inception to Date Costs Incurred	3,749
Total Expected to be Incurred	$ 3,749

Related party transactions (Details) $ in Millions	6 Months Ended
Related party transactions (Details) $ in Millions	Jun. 30, 2016 USD ($)
Related Party Transaction [Line Items]
Costs incurred from services rendered under marketing/consulting agreement	$ 0.2

Segment information (Details) $ in Thousands	3 Months Ended		9 Months Ended
Segment information (Details) $ in Thousands	Sep. 30, 2016 USD ($)	Sep. 30, 2015 USD ($)	Sep. 30, 2016 USD ($) Company Segment BusinessUnit	Sep. 30, 2015 USD ($)	Jun. 30, 2016 USD ($)	Dec. 31, 2015 USD ($)	Jun. 30, 2015 USD ($)
Segment Reporting Information [Line Items]
Number of independent public companies \| Company			2
Number of business segments \| Segment			1
Net income	$ 21,340	$ 36,943	$ 14,384	$ 29,523
Total assets	932,026		932,026			$ 1,037,484
Biodefense [Member] \| Intersegment Eliminations [Member]
Segment Reporting Information [Line Items]
External revenue	0	0	0	0
Biodefense [Member] \| Operating Segments [Member]
Segment Reporting Information [Line Items]
External revenue	0	0	0	0
Net income	$ 0	$ 0	$ 0	$ 0
Total assets					$ 0		$ 0
Aptevo [Member] \| Operating Segments [Member]
Segment Reporting Information [Line Items]
Number of business units \| BusinessUnit			1